Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3 World

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Evidence: Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312

Official URL: https://fevir.net/resources/Evidence/367932 Version: 1.0.0-ballot3
Standards status: Informative Computable Name: NCT03640312_otherOutcomeMeasure_2_OG001
Other Identifiers: FEvIR Object Identifier: FEvIR Object Identifier#367932, FEvIR Linking Identifier: NCT03640312-otherOutcomeMeasure-2--OG001, OID:2.16.840.1.113883.4.642.40.44.22.268

Copyright/Legal: Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

version: 30; Last updated: 2026-09-08 12:21:25+0000

Profile: NonComparativeEvidence

ArtifactPublicationStatus: Active

url: Evidence Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312

identifier: FEvIR Object Identifier/367932, FEvIR Linking Identifier/NCT03640312-otherOutcomeMeasure-2--OG001, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.22.268

version: 1.0.0-ballot3

name: NCT03640312_otherOutcomeMeasure_2_OG001

title: Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312

citeAs:

Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367932. Revised 2026-09-08. Available at: https://fevir.net/resources/Evidence/367932. Computable resource at: https://fevir.net/resources/Evidence/367932#json.

status: Active

date: 2026-11-05 14:34:28+0000

author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

copyright:

Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).

description:

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

variableDefinition

description:

Candesartan

note:

Outcome Measure Denominator Units: Participants

variableRole: Population

observed: Patients randomized to the comparison arm took a once daily 8mg candesartan. Candesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks. (Identifier: ClinicalTrials.gov Outcome Measurement Group Id/OG001)

variableDefinition

variableRole: Outcome

observed: Rate of Adverse Events of Special Interest at 12 weeks - (NCT03640312)

statistic

statisticType: risk

quantity: 33.33333333333333 %

numberAffected: 10

SampleSizes

-KnownDataCount
*30